よむ、つかう、まなぶ。
医薬品の一般的名称について（令和6年3月11日医薬薬審発0311第1号） (13 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/hourei/doc/tsuchi/T240312I0010.pdf |
| 出典情報 | 医薬品の一般的名称について（3／11付 通知）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
1,4,7,35-tetraoxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontan-37-yl]-2,5-dioxopyrrolidin-3-yl
group (C75H102N9O23; molecular weight: 1,497.66)), which is composed of pyrrolobenzodiazepine dimer and linker,
attached to an average of 2-3 cysteine residues of the recombinant monoclonal antibody. The antibody moiety is a
recombinant anti-CD19 monoclonal antibody whose variable regions are derived from mouse antibody and other
regions are derived from human IgG1, and the C-terminal K450 is deleted in the H-chain. The antibody is produced
in CHO cells. The protein moiety is a glycoprotein (molecular weight: ca. 147,000) composed of 2 H-chains (γ1chains) consisting of 449 amino acid residues each and 2 L-chains (κ-chains) consisting of 211 amino acid residues
each.
group (C75H102N9O23; molecular weight: 1,497.66)), which is composed of pyrrolobenzodiazepine dimer and linker,
attached to an average of 2-3 cysteine residues of the recombinant monoclonal antibody. The antibody moiety is a
recombinant anti-CD19 monoclonal antibody whose variable regions are derived from mouse antibody and other
regions are derived from human IgG1, and the C-terminal K450 is deleted in the H-chain. The antibody is produced
in CHO cells. The protein moiety is a glycoprotein (molecular weight: ca. 147,000) composed of 2 H-chains (γ1chains) consisting of 449 amino acid residues each and 2 L-chains (κ-chains) consisting of 211 amino acid residues
each.